Market Overview

Tickers

Articles

Keywords

Search by keyword...
googlecse

CombiMatrix's Pre-Implantation Genetic Screening Approval Highlights Today's Pre-Market Biotech Roundup

BRYAN FINNIGAN , Benzinga Staff Writer  
November 29, 2016 9:42am   Comments
Share:
CombiMatrix's Pre-Implantation Genetic Screening Approval Highlights Today's Pre-Market Biotech Roundup
  • CombiMatrix Corp (NASDAQ: CBMX): Granted approval for pre-implantation genetic screening and conditional approval from NYS Department of Health.
  • CytRx Corporation (NASDAQ: CYTR): Announced Aldoxorubicin achieved primary endpoint, stating, “Statistically significant improvement in progression-free survival in patients with Liposarcoma." The company expects to submit an NDA with the FDA for Aldoxorubicin as treatment for patients with relapsed or refractory STS in 2017.
  • Dimension Therapeutics Inc (NASDAQ: DMTX) Received positive opinion for DTX401 for European orphan drug designation.
  • KemPharm Inc (NASDAQ: KMPH): Received FDA clearance to initiate KP201/IR trial.
  • Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA): Announced Phase III for M923 met primary endpoint and all secondary endpoints.
  • Novan Inc (NASDAQ: NOVN): Announced Phase II trial achieved significant results.
  • Vascular Biogenics Ltd (NASDAQ: VBLT): Announced VB-111 met primary endpoint, stating, "[It] shows evidence of overall survival rate."

    • All data compiled using Benzinga Pro. 

    © 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

     

    Related Articles (CBMX + CYTR)

    View Comments and Join the Discussion!

    Posted-In: Biotech News Health Care Movers & Shakers FDA Movers Tech Trading Ideas

    Don't Miss Any Updates!
    News Directly in Your Inbox
    Subscribe to:
    Benzinga Premarket Activity
    Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
    Market in 5 Minutes
    Everything you need to know about the market - quick & easy.
    Fintech Focus
    A daily collection of all things fintech, interesting developments and market updates.
    Thank You

    Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com